Stephen Blake

PhD, BSc

  • 766 Citations
  • 14 h-Index
20082019
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Stephen studied Immunology and Biochemisty at the University of Adelaide, graduating with first class honours in 2004. He continued his study in Adelaide, undertaking a PhD at the University of Adelaide and Hanson Institute. During this period he evaluated how tyrosine kinase inhibitors, an emerging therapy for chronic myeloid leukemia also can dampen host immune responses. In 2009 he moved to Brisbane to take up a University of Queensland Postdoctoral Fellowship at the Diamantina Institute. Here he worked to develop novel cancer therapies to enhance host immune responses against cancer cells. These included dual functional siRNA that could both inhibit oncogene expression in cancer cells and activate host immune responses through TLR7 signalling. He also evaluated the role of the T-cell checkpoint PD-1 in mediating T-cell tolerance and how blockade can enhance adoptive immunotherapy in tumor bearing mice. This interest in immunotherapy was continued as he moved to the QIMR-Berghofer institute in Brisbane. During this period his worked helped identify new members of the nectin interacting receptors as potential targets to enhance natural killer cell control of metastases. He was also involved in developing a pre-clinical model to test for toxicity and anti-tumor efficacy of novel immunotherapies before they are used in patients. Stephen moved back to Adelaide in 2016 to join David Lynn’s group at SAHMRI to investigate the how microbiome dysregulation can alter immune responses.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2019

  • 766 Citations
  • 14 h-Index
  • 20 Article
  • 2 Letter
  • 2 Review article
1 Citation (Scopus)

CD96 Is an Immune Checkpoint That Regulates CD8 + T-cell Antitumor Function

Mittal, D., Lepletier, A., Madore, J., Aguilera, A. R., Stannard, K., Blake, S., Whitehall, V. L. J., Liu, C., Bettington, M. L., Takeda, K., Long, G. V., Scolyer, R. A., Lan, R., Siemers, N., Korman, A., Teng, M. W. L., Johnston, R. J., Dougall, W. C. & Smyth, M. J., 1 Apr 2019, In : Cancer Immunology Research. 7, 4, p. 559-571 13 p.

Research output: Contribution to journalArticle

7 Citations (Scopus)

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis

Harjunpää, H., Blake, S., Ahern, E., Allen, S., Liu, J., Yan, J., Lutzky, V., Takeda, K., Aguilera, A. R., Guillerey, C., Mittal, D., Li, X. Y., Dougall, W. C., Smyth, M. J. & Teng, M. W. L., 3 Jul 2018, In : OncoImmunology. 7, 7, e1445949.

Research output: Contribution to journalArticle

Early-life antibiotic-driven dysbiosis leads to dysregulated vaccine immune responses in mice

Lynn, M., Tumes, D., Choo, J., Sribnaia, A., Blake, S., Leong, L., Young, G., Marshall, H., Wesselingh, S., Rogers, G. & Lynn, D., 2018, In : Cell Host & Microbe . 23, p. 1-8

Research output: Contribution to journalArticle

Open Access
File
88 Citations (Scopus)

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., Yan, J., Bartholin, L., Lee, J. S., Vivier, E., Takeda, K., Messaoudene, M., Zitvogel, L., Teng, M. W. L., Belz, G. T., Engwerda, C. R. & 4 othersHuntington, N. D., Nakamura, K., Hölzel, M. & Smyth, M. J., 31 Jul 2017, In : Nature Immunology.

Research output: Contribution to journalArticle

21 Citations (Scopus)

Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor

Ngiow, S. F., Young, A., Blake, S. J., Hill, G. R., Yagita, H., Teng, M. W. L., Korman, A. J. & Smyth, M. J., 1 Nov 2016, In : Cancer Research. 76, 21, p. 6266-6277 12 p.

Research output: Contribution to journalArticle